BIOGEN INC. - COMMON STOCK

ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.

14 дек 2023 06:30:00 Источник Nasdaq GlobeNewswire

Biogen Appoints Monish Patolawala to its Board of Directors

06 ноя 2023 07:30:00 Источник Nasdaq GlobeNewswire

Eisai Presents New LEQEMBI® (lecanemab-irmb) Investigational Subcutaneous Formulation Interim Study Results and Clinical Improvement Data in Earlier Stages of Early Alzheimer’s Disease From Additional Analyses of Clarity AD at The Clinical Trials On Alzheimer’s Disease (CTAD) Conference

25 окт 2023 17:26:00 Источник Nasdaq GlobeNewswire

New Data from Biogen’s Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimer’s Disease

25 окт 2023 10:51:00 Источник Nasdaq GlobeNewswire

Biogen to Present New Data at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 Meeting

19 окт 2023 07:30:00 Источник Nasdaq GlobeNewswire

FDA Approves Biogen’s TOFIDENCE™ (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA®

29 сен 2023 16:06:00 Источник Nasdaq GlobeNewswire

Biogen Completes Acquisition of Reata Pharmaceuticals

26 сен 2023 08:59:54 Источник Nasdaq GlobeNewswire

LEQEMBI® Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Japan

25 сен 2023 01:02:57 Источник Nasdaq GlobeNewswire

Biogen Appoints Jane Grogan as Head of Research

06 сен 2023 07:30:00 Источник Nasdaq GlobeNewswire

FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder

04 авг 2023 22:41:32 Источник Nasdaq GlobeNewswire

Biogen to Acquire Reata Pharmaceuticals

28 июл 2023 07:05:44 Источник Nasdaq GlobeNewswire

Eisai Presents Latest Analysis of Lecanemab’s Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer’s Association International Conference (AAIC) 2023

19 июл 2023 19:30:00 Источник Nasdaq GlobeNewswire

FDA Grants Traditional Approval for LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer’s Disease

06 июл 2023 20:00:00 Источник Nasdaq GlobeNewswire

New Data at Cure SMA Highlight Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs After Gene Therapy

30 июн 2023 16:06:00 Источник Nasdaq GlobeNewswire

Biogen Announces Changes to Its Board of Directors

12 июн 2023 17:14:01 Источник Nasdaq GlobeNewswire

FDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer’s Disease

09 июн 2023 18:45:00 Источник Nasdaq GlobeNewswire

Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer’s Disease

15 май 2023 19:30:00 Источник Nasdaq GlobeNewswire

FDA Grants Accelerated Approval for QALSODY™ (tofersen) for SOD1-ALS, a Major Scientific Advancement as the First Treatment to Target a Genetic Cause of ALS

25 апр 2023 15:04:23 Источник Nasdaq GlobeNewswire

Biogen Appoints Adam Keeney as Head of Corporate Development

04 апр 2023 07:30:00 Источник Nasdaq GlobeNewswire

Additional Detailed Analyses From Phase 2 Study 201 of Lecanemab Published as Three Papers in Peer-Reviewed Journals

30 мар 2023 19:30:00 Источник Nasdaq GlobeNewswire